229 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1226)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (18)
- Bone & Muscle (10)
- Cancer (100)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (22)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (13)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (188)
- Heart Disease (129)
- Infectious Disease (50)
- Insomnia (3)
- Kidney Disease (12)
- Liver Disease (55)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (125)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (56)
- Pain Management (1)
- Pediatrics (97)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (46)
- Urology (3)
- Vascular Conditions (10)
Displaying 1 - 4 of 4
Condition: Addiction / Alcohol
Investigator: A. Benjamin Srivastava, MD
Status: Currently Recruiting
Columbia University Medical Center is recruiting individuals ages 21-55 who are seeking treatment for alcohol problems to participate in a research study involving treatment. For your participation, you'll receive treatment with disulfiram (brand name Antabuse) at no cost. You be treated with disulfiram for approximately 13 weeks and undergo brain…
Condition: Cancer / Kidney Cancer
Investigator: Emerson Lim, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including cancer cells. By attaching to cancer…
Condition: Liver Disease / Hepatic Encephalopathy
Investigator: Robert Brown, MD, MPH
Status: Closed
The purpose of this study is to find out how doctors describe hepatic encephalopathy episodes in patients medical records in the course of their regular practice. The aim of the study is simply to collect information from their medical records about how their episodes of overt hepatic encephalopathy are described. There is nothing that will be required of…
Condition: Liver Disease / Hepatic Encephalopathy
Investigator: Robert Brown, MD, MPH
Status: Closed
The purpose of this study is to compare the time to onset of an episode of overt HE, in subjects with previously demonstrated overt HE after treatment with rifaximin 550 mg BID and lactulose, or rifaximin 550 mg BID. Subjects will be screened to confirm eligibility into the study. Once confirmed, subjects will begin the treatment phase and will be randomly…